Table 2.

Achievement of clinical and treatment targets comparing trial groups over time

TimeExperimental Intervention Number (%)Standard Care Control Number (%)P
BP ≤130/80Baseline139/236 (59)101/235 (43)0.03a
12 months134/218 (61.5)100/218 (45.9)0.47b
24 months81/128 (63.2)64/136 (47)0.76c
LDL <2.5 mmol/LBaseline99/230 (43)81/220 (36.8)0.41a
12 months97/206 (47.1)99/214 (46.3)<0.001b
24 months78/122 (63.9)76/128 (59.4)0.74c
On RAAS blockerBaseline165/236 (70)156/235 (66)0.49a
12 months165/219 (75)146/220 (66)0.92b
24 months102/130 (78)92/140 (66)0.06c
Hba1c ≤7.0% in diabeticsBaseline38/68 (55.9)36/74 (48.6)0.58a
12 months50/70 (71.4)52/77 (67.5)<0.001b
24 months40/49 (81.6)43/52 (82.7)0.76c
Hemoglobin ≥105 g/LBaseline229/235 (97.4)232/234 (99.1)0.81a
12 months208/214 (97.2)203/214 (94.8)0.07b
24 months125/128 (97.7)130/136 (95.6)0.64c
Iron saturation ≥0.2Baseline169/225 (75.1)160/226 (70.8)0.28a
12 months154/210 (73.3)155/210 (73.8)0.24b
24 months95/128 (74.2)95/124 (76.6)0.31c
Serum phosphate <1.8 mmol/LBaseline235/235 (100)233/233 (100)NA
12 months211/211 (100)218/218 (100)NA
24 months125/126 (99.2)126/127 (99.2)NA
Bicarbonate ≥22 mmol/LBaseline225/234 (96.1)230/234 (98.3)0.18a
12 months209/215 (97.2)212/214 (99.1)0.68b
24 months124/127 (97.6)124/127 (97.6)0.37c
  • All of the P values are from generalized estimating equations. NA, statistical analysis is not applicable as target was almost uniformly met. RAAS, renin-angiotensin-aldosterone.

  • a Comparison at baseline.

  • b Comparison over time within group.

  • c Comparison between groups over time adjusted for baseline.